J&J's William Weldon: Leadership in a Decentralized Company

Knowledge at Wharton

Ask about Knowledge at Wharton

Episode Description

Consumers tend to associate Johnson & Johnson with Band-Aids and baby shampoo, but those well-known products are only part of a much larger picture, according to William Weldon, chairman and CEO of the New Brunswick, N.J.-based firm. In fact, Weldon has the mind-boggling task of overseeing more than 200 operating companies across three sectors, including consumer products, pharmaceuticals and medical devices. On June 18, Weldon spoke at the 2008 Wharton Leadership Conference about the challenges of running the Johnson & Johnson family of companies. In an interview with Knowledge@Wharton, he elaborated on how J&J's decentralized structure informs his leadership style and what he sees as key issues for the health care industry in the coming decade, among other topics.

Read the full transcriptHide the full transcript
  1. [Music] This podcast is brought to you by Knowledge at Wharton. Please visit knowledge.warton.upen.edu
  2. for more information. [Music] Consumers tend to associate Johnson and Johnson with band-aids and baby shampoo.
  3. But those well-known products are only part of a much larger picture, according to William Weldon, chairman and CEO of
  4. the New Brunswick, New Jerseybased firm. In fact, Weldon has the mind-boggling task of overseeing more than 200
  5. operating companies across three sectors, including consumer products, pharmaceuticals, and medical devices. On
  6. June 18th, Weldon spoke at the 2008 Wharton Leadership Conference about the challenges of running the Johnson and
  7. Johnson family of companies. In an interview with Knowledge at Wharton, he elaborated on how J&J's decentralized
  8. structure informs his leadership style and what he sees as key issues for the healthcare industry in the coming decade
  9. among other topics. Mr. Weldon, thanks for joining us today. It's great to be here. Many of our readers are familiar
  10. with Johnson and Johnson consumer products, but they may not be familiar with uh the Johnson and Johnson family
  11. of companies and what that actually encompasses. Can you give us an overview? The way the way we look at our
  12. organization is really that we have three business segments we work in. One is the uh consumer business which you
  13. alluded to which is a lot of the baby products um uh baby shampoo, baby powder um band-aids but then it also includes
  14. Neutrogena and Aino and and many of the uh other uh a lot of consumer companies that people would not know belong to the
  15. J&J family. The second part of our business is our medical device and and diagnostics business, which by itself is
  16. the largest medical device and diagnostics business in the world. And that consists of everything from
  17. cardiovascular products for stances to joint replacements for knees and hips to lenses with acu and um blood glucose
  18. meters uh surgical uh ethicon sutures and endoscopic instruments. So it covers a broad array of of products. And then
  19. we have our pharmaceutical business which is our largest segment. and it's over 40% of our business and that really
  20. deals with cardiovascular products uh oncology products uh immune mediated for rheumatoid arthritis and and uh those
  21. types of areas. So a lot in the verology area for HIV AIDS and tuberculosis. So when you when you look at J&J, most
  22. people think of it as the consumer side, but um it's actually our smallest portion of the business and um it's
  23. about uh we have about 61 billion in revenue and anywhere from 180 to 200 billion in market cap. What are the main
  24. challenges of leading in a decentralized corporate environment including across countries and cultures? You know, it's
  25. it's interesting. I I think there's pluses and minuses to decentralized and centralized. I think J&J is probably the
  26. reference company for being decentralized. You know, there are challenges to it and
  27. that is that you don't have as much control as you may in a centralized company. But the the good part of it is
  28. that you have wonderful leaders, you have great people that you have a lot of confidence and faith in and they run the
  29. businesses. So if you look at it that uh if you take Japan for example, we have local management running the companies.
  30. They understand the consumer, they understand the people they're dealing with and they understand the government
  31. and the needs in the marketplace. whereas it's very hard to run it from the US and and think that we we would
  32. know enough to be able to do this. So I I think it really affords us a lot of opportunities by being decentralized.
  33. What you do lose is control. But with our Kredo and with the the value system that we work under, we feel very very
  34. confident about our leadership and our management and you have to have trust and confidence in them. I think the
  35. other thing that decentralization does is it gives you a tremendous opportunity to develop people. So you give them a
  36. lot of opportunity to work in different areas to work in smaller companies to make mistakes and work and ultimately
  37. move into larger companies. I also think the benefit of the cultural side that you asked about is that you do have
  38. local people running the businesses. So the men and women that run our businesses around the world usually are
  39. are people that grew up in those markets, understand those markets and develop themselves in those markets. So
  40. they can relate to the needs of the of the customer, whoever that customer may be. So, so the challenge really I you
  41. know I see it a great uh a great benefit rather than a challenge because the problem with centralization is if one
  42. person makes one mistake it can the whole organization. This way you've got wonderful people running businesses
  43. uh you have to have confidence in them but you let them run it and you don't have to worry about uh making that one
  44. big mistake. When you became CEO in 2002 what was the biggest challenge you faced
  45. and how did you overcome it? Um, you know, I think the challenges always are is it's around the area of
  46. people and making sure you have the enough really outstanding leaders to run the businesses. We just talked about
  47. decentralization and and uh and and allowing people to run the business. We have over 200 operating companies. We
  48. need 200 great leaders. I think the challenge is always developing the great leaders that can run the businesses. I
  49. think that's always the biggest challenge. I think the thing that that really is the challenge for anybody who
  50. goes into a role like I went into is worrying about who's going to sit here next. I mean, it's a responsibility
  51. where you have, you know, you can think about shareholders, but you think about the 120,000 plus employees and families
  52. that we're responsible to and you want to make sure when when you leave that you're leaving it in hands of people
  53. that you feel are you're very comfortable with. You could go on and talk about we had we had challenges in
  54. our pharmaceutical pipeline and we had to really revamp and do a lot of things in in our R&D organization to make sure
  55. that we strengthened our pipeline. Um because it really is when you think about it's dependent upon people and
  56. pipeline. So you look at pipeline of people and pipeline of products and those are the two things that I think we
  57. have to be focused on all the time. Your field like many requires a heavy focus on innovation in order to stay ahead.
  58. How does Johnson and Johnson's uh decentralized corporate structure um relate to innovation? How does it
  59. enhance it? Well, I think I think what decentraliz where decentralization helps in innovation is that it allows
  60. different people with different you know different skills, different thoughts and
  61. bring together different products and technologies to satisfy unmet you know needs of of patients or or customers. So
  62. for example, if you look at um we had a meeting where we brought together our engineers from our MD and D group and
  63. our scientists from our pharmaceutical businesses and they came up with putting a drug on a stent and and developed the
  64. drug alluding stent for cardiovascular disease which was a huge breakthrough and it it actually brought the skills
  65. and knowledge from two different sets of people together. We're now working on a
  66. product that we just launched in Europe and we'll launch here shortly which did the same thing. It brought the skills of
  67. the engineers together with the skills of the scientists to to develop a basically a patch which will deliver a
  68. narcotic for post-operative use. So the patients don't have to carry around the PCA pumps and everything else with them
  69. all the time. They just touch it. It's about the size of a credit card. You hit it and you get your dose of narcotic and
  70. it has a battery which makes sure it's delivered properly in the right amount, the right time, right frequency. Um so
  71. so you look at the convergence of these skills and technologies and products and
  72. then people and I think it offers us a distinct competitive advantage. If you fast forward into the future, I think
  73. you're going to see a lot more personalized medicine. So we're going to look at biomarkers and genomics and
  74. genetics and and we're going to be able to identify who will respond to a product, who won't respond, who will get
  75. a side effect, who won't get a side effect. And that takes the skills of our diagnostics group and our pharmaceutical
  76. group and putting them together to identify the patient that will will respond to these products. So I think
  77. that the decentralization and having these this broad array of companies actually um fosters innovation and
  78. stimulates each other who are working in similar areas. And what are the downsides to that structure? Uh with so
  79. many subsidiaries I imagine that coordination must become quite an issue. I think yeah I think you hit upon it. I
  80. think the downside to decentralization or or in in this area of innovation is actually the coordination. Um it's
  81. trying to get people, you know, together moving in the same direction. One of one
  82. of the real challenges is that as I said before, we have our pharmaceutical group, our medical device and
  83. diagnostics and our consumer group. Well, they each have their responsibilities in their in the markets
  84. they compete in. So when we try and bring people together across the different groups, sometimes, you know,
  85. there's there's enough to do in their own group that now we're asking them to cross boundaries and work together. And
  86. sometimes we'll set up skunk work groups where we'll send them off on their own.
  87. We call that our internal ventures where we we'll do those things. Um but but that is that is the challenge is the
  88. coordination. Not so much there's that there's replication but finding the right people to be able to give the
  89. resources to this convergence of technologies as opposed to just working in their own areas. If you if you look
  90. at straight innovation as you would in any pharmaceutical group or medical device or consumer group we have all
  91. those working in our R&D organizations in each of those. It's the ability to work across the boundaries that really
  92. brings true innovation I think and and is going to take some real breakthroughs and bring real breakthroughs in the
  93. future. But it also does take some coordination and some some sacrifice from the individuals. So that that is
  94. the toughest thing is getting people to get outside of the silos that they work in and work across the groups. Can you
  95. identify uh the formal and informal ways that Johnson and Johnson identifies new
  96. innovations? Yeah, we have we have a few things. One one thing is we have what we
  97. call internal ventures. And the internal ventures would be uh somebody working in
  98. the organization or a group of people who may put forward a recommendation of something that could be done. We're
  99. we're doing a lot of work in stem cells for example where none of the groups will take ownership with it but there's
  100. a great opportunity there. So they put together a business plan, present it, put together a budget with it and then
  101. we allow that group to go off and work on that. We we create other environments. For example, if we're were
  102. looking at the area of oncology where we may bring people from the consumer pharmaceutical and medical device and
  103. diagnostics groups together to share what they're doing and out of that we'll you know basically they will generate
  104. ideas where they can work together to to bring products forward and it's usually
  105. better when they generate them than when we try and impose upon them. We did do a
  106. a review of our pipeline um probably about a year ago and we found that there were 80 products in our pipeline that
  107. had some form of convergence that was necessary. Now the important thing for us to do is to make sure that we
  108. understand the value that those bring and maybe of the 80 of them we ought to work on a half a dozen of them and it's
  109. being able to to bring those down into a focused area. We have another another product going on in our medical device
  110. group and our ethicon group which is primarily in the suture and wound closure area that is um needing the
  111. skill sets of the people in our biotechnology area and it's um actually a product to stop bleeding serious
  112. bleeding but it has to have a bio base on it. So we brought actually scientists from the biotechnology area over to work
  113. specifically in the ethicon group to work in that area. So it's uh you know we we have a lot of both formal and
  114. informal ways that we create this environment and probably the last thing we do which has been very successful is
  115. we've created an our own internet for our scientists so they can go on and see what others are doing communicate with
  116. each other so that if there's an interest in one area they can get scing about those areas and working together
  117. to to bring products to the market. What are the major challenges facing drug and
  118. healthcare companies both in the US and abroad? Yeah, I I think probably the single, you know, if it's not the single
  119. largest, but if you look at the cost of health care, um, you know, I think it's it's a responsibility we all have to
  120. figure out how do we get it better under really under control. Um, and it's driven by demographics. It's driven by,
  121. you know, the aging population, the emerging middle class in other parts of the world and technology. And people
  122. want to live longer. They want to live better. They want to live healthier. So I think we have we have a couple
  123. responsibilities. One is to get up front and look at prevention and wellness and
  124. healthy people and how do you keep them healthy and then treat them on the other
  125. end where they need the treatment. So I think the cost of healthcare is a big challenge. I think the regulatory
  126. environment has become another huge challenge. I think that um people are looking for products that can be risk-f
  127. free and there you know you get up on a morning and you walk across the street that's not risk- free. So don't think
  128. that you're going to be able to deliver a product in a patient. Drugs by definition have good effects and side
  129. effects. I've had a knee replaced and you know there's a risk associated with having your knee replaced. Mine's worked
  130. out extremely well, but it could have also gone another way. you can there's all kinds of of issues there and I think
  131. that the everybody's looking for this risk-free environment and it's not risk- free. It's uh there are risks associated
  132. with it. I think we have to define them. We have to do good research. We have to
  133. look at evidence-based medicine and see what's what's going to come out of it. But I think the regulatory environments
  134. have become somewhat um uh risk averse if you will and trying to find out everything. and until you get out into
  135. usually into patients many times you don't find everything out because of the way somebody may use a product or
  136. whatnot. So, so I think it is in the area of cost control. I think it is in the area of regulatory are probably the
  137. two biggest no matter where you look in the world um barriers that we have to overcome. And it puts the onus on I
  138. think the industry. Um and this isn't all bad. Puts the onus on us to do better work when we do our clinical
  139. trials, when we do our research, when we when we we have full transparency and disclosure. I think that's that's really
  140. important. Um, and I think it comes to the ability of the regulatoratory bodies and industry to work together. And we've
  141. been advocates of strengthening the regulatory bodies because the stronger they are in science, the stronger it'll
  142. force us to be and the better it'll be for patients. Um, and then and then the cost side, we just have to be willing to
  143. step up and make sure that we are and I think the industry does support indigent
  144. people. um you know we've we've done we've we've actually supported in subsahara Africa HIV products we've made
  145. available there at at very low prices if there are indigent patients here in the
  146. United States they just have to file a form with ourselves or any other pharmaceutical company and we'll supply
  147. them products free of charge if they qualify which is you know a very low level to qualify so I think we're doing
  148. all we can but I think we have to continue to do more Johnson and Johnson has operated in India for more than 50
  149. years now and recently there was a big shakeup among drug companies there when a Japanese firm Dichi Sano bought out
  150. Ramaxi. What is what is your view on that deal and does it say anything about the state
  151. of the pharmaceutical industry in India? Well, I think 70 you know I I could be wrong on this but I think about 70% of
  152. drugs dispensed are generics here in the United States today. Um there's a big opportunity in the generic field because
  153. of large products going off patent. Um but I think if you are a researchbased company um you need to really commit
  154. yourself to research. Um if you're a company committed to your employees, you need to make sure they're treated
  155. appropriately and and properly and and there's costs associated with that. So I think what what it really comes down to
  156. that there there is a need for generic companies, good generic companies. Um a model that some you know companies may
  157. want to choose is to go both generic and ethical pharmaceuticals let's call them
  158. or or or researchbased drugs. Um so it's each each company has their own choices
  159. that they have to make. Personally, I think that if you have good research, you understand the needs of patients,
  160. and you can deliver good products into the market, that's the most important thing to be doing, and that's where
  161. where we've committed ourselves so far, but um that's not to say that that we wouldn't go into to generics or other
  162. companies. And and I don't think, you know, I think that there's a big market emerging, big opportunities in the
  163. future. And I think it's uh each company has their own business model that they think is the the best for them. Some may
  164. be to both be a researchbased and a and a generic company. Others just research based and others just generic based. So
  165. I think it's a it's an individual choice. But I think as you as as the generic industry has evolved, it's
  166. evolved into very good products um and that many reputable companies are going there and feeling that that's part of
  167. the model that they want to choose. So I think it's just really personal choice for the company. Thank you very much for
  168. speaking with us today. Thank you. [Music] For more information, please visit knowledge.warton.upen.edu.
  169. [Music]

Brief Summary

William Weldon discusses Johnson & Johnson's decentralized structure, leadership challenges, and innovation strategies in healthcare.

Key points

  • Decentralization at J&J. Weldon explains how J&J's decentralized structure fosters leadership and innovation.
  • Challenges in Healthcare. Weldon outlines the major challenges facing the healthcare industry today.
  • Risks in Pharmaceuticals. Weldon discusses the inherent risks associated with drugs and healthcare.

Tension

45/ 100Some tension

Related episodes